Cytosorbents Co. (NASDAQ:CTSO) CFO Kathleen P. Bloch sold 11,176 shares of the company’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $8.25, for a total value of $92,202.00. Following the sale, the chief financial officer now directly owns 261,246 shares of the company’s stock, valued at $2,155,279.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
CTSO opened at $7.60 on Wednesday. Cytosorbents Co. has a fifty-two week low of $3.30 and a fifty-two week high of $8.25. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.64 and a quick ratio of 2.54. The stock has a market cap of $216.61, a PE ratio of -23.75 and a beta of -0.08.
Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, March 8th. The medical research company reported ($0.12) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). Cytosorbents had a negative return on equity of 118.07% and a negative net margin of 52.08%. The firm had revenue of $4.65 million for the quarter, compared to analysts’ expectations of $4.56 million. research analysts forecast that Cytosorbents Co. will post -0.47 EPS for the current fiscal year.
CTSO has been the subject of several analyst reports. Maxim Group set a $12.00 target price on Cytosorbents and gave the company a “buy” rating in a report on Monday, January 8th. ValuEngine downgraded Cytosorbents from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. HC Wainwright set a $14.00 price objective on Cytosorbents and gave the stock a “buy” rating in a research note on Friday, March 9th. B. Riley reissued a “buy” rating and issued a $11.25 price objective on shares of Cytosorbents in a research note on Thursday, January 25th. Finally, Cowen set a $9.00 price objective on Cytosorbents and gave the stock a “buy” rating in a research note on Thursday, March 8th. Six equities research analysts have rated the stock with a buy rating, Cytosorbents currently has a consensus rating of “Buy” and a consensus target price of $11.05.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN increased its holdings in shares of Cytosorbents by 182.3% during the 4th quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 13,515 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in shares of Cytosorbents during the 4th quarter valued at about $146,000. Fortaleza Asset Management Inc. increased its holdings in shares of Cytosorbents by 60.9% during the 4th quarter. Fortaleza Asset Management Inc. now owns 37,615 shares of the medical research company’s stock valued at $244,000 after acquiring an additional 14,240 shares during the last quarter. Wealthcare Advisory Partners LLC acquired a new position in shares of Cytosorbents during the 3rd quarter valued at about $365,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Cytosorbents during the 4th quarter valued at about $396,000. 10.84% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/04/11/insider-selling-cytosorbents-corp-ctso-cfo-sells-11176-shares-of-stock.html.
Cytosorbents Company Profile
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.